Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid Tumors

Solid Tumors Clinical Trial

Official title:

A Tolerance, Safety and Pharmacokinetic Ascending Dose Phase I Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive Malignant in Advanced Malignant Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02881190
• Other study ID #: C002 CANCER
• Status: Completed
• Phase: Phase 1
• Start date: December 14, 2015
• Est. completion date: November 8, 2019

Study information

• Verified date: June 2020
• Source: RemeGen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A tolerance, safety and pharmacokinetic ascending dose phase I Study of RC48-ADC administered intravenously to subjects with HER2-positive malignant in advanced malignant solid tumors.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 57
• Est. completion date: November 8, 2019
• Est. primary completion date: June 27, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Signed informed consent form;

• Aged 18-75 years;

• ECOG physical condition is 0 or 1;

• Life expectancy greater than 12 weeks;

• Patients with locally advanced or metastatic malignant solid tumors diagnosed by pathology and refractory to standard of care therapy, or for whom no standard of care therapy is available histology standard of care therapy, or for whom no standard of care therapy is available;

• Human epidermal growth factor receptor 2 (HER2)-positive refers to immunohistochemistry (IHC 2+or 3+);

• Patients with measurable and appreciable tumor lesions according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1);

• Adequate organ function as defined by the following criteria:

• absolute neutrophil count(ANC) >= 1.5 x 10(9)/L;

• platelets>=100*10(9)/L;

• Total serum bilirubin <=1.5*ULN;

• serum aspartate transaminase (AST) and serum alanine transaminase (ALT) <=3.0*upper limit of normal (ULN), or AST and ALT<=5*ULN if liver function abnormalities are due to underlying malignancy;

• normal serum creatinine;

• international normalized ratio(INR) and activated partial thromboplastin time (aPTT) must be less than or equal to 1.5 times the upper limit of the normal range (ULN);

• Women of child-bearing potential and men must agree to use adequate contraception (e.g., condoms, implants, injectables, combined oral contraceptives, some intrauterine devices [IUDs], complete sexual abstinence, or sterilized partner) prior to study entry and during the period of therapy and for 30 days after the last dose of study drug;

• Left ventricular ejection fraction (LVEF) >= 50% as assessed by echocardiogram.

Exclusion Criteria:

• Current pregnancy or lactation;

• Serologic status reflecting active hepatitis B or C infection;

• Major surgery within 4 weeks of first dose of study drug and not fully recovered

• Receiving palliative radiation therapy for bone metastases if administered <= 2 weeks prior to first study treatment;

• Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version 4), grade less than or equal to1, or to the levels dictated in the inclusion/exclusion criteria with the exception of alopecia;

• Prior-treatment with other clinical research anticancer drugs within 28 days before study drug treatment;

• The active infection with clinical significance According to the researcher's judgment,

• Known history of immune deficiency,including HIV-positive or other known acquired or congenital immunodeficiency, or organ transplantation;

• Currently active clinically significant cardiovascular disease such as uncontrolled arrhythmia, congestive heart failure, or greater than or equal to Class 2 congestive heart failure as defined by the New York Heart Association Functional Classification, or history of myocardial infarction unstable angina, or acute coronary syndrome within 6 months prior to enrollment in the study;

• Unwilling or unable to participate in all required study evaluations and procedures;

• The time interval which is from the last chemotherapy or HER2 targeted therapy until the first trial is more than 21 days;

• Patients who had received systemic steroid therapy for a long time (Patients who had received systemic steroid therapy for short time and stopped drug more than 2 weeks could be enrolled);

• Serious complications such as active alimentary tract hemorrhage, intestinal obstruction, enteroparalysis, interstitial pneumonia, pulmonary fibrosis, renal failure, glaucoma and uncontrolled diabetes;

• Uncontrolled primary or metastatic tumor of brain;

• Current peripheral neuropathy of Grade = 2;

• History of nerve or psychiatric disorders.

Related Conditions & MeSH terms

• Neoplasms
• Solid Tumors

Intervention

Drug:
• RC48-ADC

Locations

Country	Name	City	State
China	Beijing Cancer Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
RemeGen

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximal Tolerance Dose (MTD) of RC48-ADC	The dose level in which >= 2 out of 6 patients have dose-limiting toxicity (DLT). The MTD is defined as the previous dose level.	DLT will be evaluated on Day 28 during cycle 1
Secondary	Safety (the drug safety as assessed by NCI-CTCAE v4.0)	The drug safety as assessed by NCI-CTCAE v4.0	up to 2 years